SCHEMBL8020845

SCHEMBL8020845

CC1(C)C(=O)N(c2cccc(Oc3ccccc3)c2)C(=O)N1Cc1ccccc1Oc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R8 Q9NYW2 7/20 0.44
MCHR1 Q99705 3/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 2/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
FAAH O00519 1/20 0.40
AR P10275 1/20 0.39
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
CYP19A1 P11511 1/20 0.38
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
RIPK1 Q13546 1/20 0.37
SLC6A2 P23975 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8027020 0.93 MCHR1 (0.48) TAS2R8MCHR1FAAHHCRTR1HCRTR2
SCHEMBL8023307 0.93 TAS2R8 (0.47) TAS2R8FAAHHCRTR1HCRTR2CYP19A1
SCHEMBL8020943 0.92 SLC6A4 (0.43) TAS2R8MCHR1MEN1ALDH1A1KMT2A
SCHEMBL8021399 0.91 TAS2R8 (0.42) TAS2R8MCHR1FAAHARHCRTR1
SCHEMBL12873219 0.91 HTR2A (0.43) TAS2R8MCHR1ARSLC6A4
SCHEMBL8021401 0.91 TAS2R8 (0.46) TAS2R8FAAHARCYP19A1HDAC1
SCHEMBL8003691 0.91 TAS2R8 (0.41) TAS2R8MCHR1KDM4EMEN1ALDH1A1
SCHEMBL12873242 0.91 MCHR1 (0.42) TAS2R8MCHR1KDM4EMEN1ALDH1A1
SCHEMBL8015496 0.90 HSD11B1 (0.41) TAS2R8MCHR1FAAHARHCRTR1
SCHEMBL8003623 0.90 MCHR1 (0.46) TAS2R8MCHR1ALDH1A1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046185-A1 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-02-24 US disclosed
US-20110046185-A1 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-02-24 US disclosed
WO-2009097998-A1 ARYLCHALCOGENO-ARYLALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF SANOFI-AVENTIS (FR) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046185-A1 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof PGC, LIPC, CEL TAS2R8 318/4885MCHR1 2815/4885KDM4E 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.